Cargando…

COVID-19 Patient-Reported Symptoms Using FLU-PRO Plus in a Cohort Study: Associations With Infecting Genotype, Vaccine History, and Return to Health

BACKGROUND: Patient-reported outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are an important measure of the full burden of coronavirus disease (COVID). Here, we examine how (1) infecting genotype and COVID-19 vaccination correlate with inFLUenza Patient-Reported O...

Descripción completa

Detalles Bibliográficos
Autores principales: Richard, Stephanie A, Epsi, Nusrat J, Lindholm, David A, Malloy, Allison M W, Maves, Ryan C, Berjohn, Catherine M, Lalani, Tahaniyat, Smith, Alfred G, Mody, Rupal M, Ganesan, Anuradha, Huprikar, Nikhil, Colombo, Rhonda E, Colombo, Christopher J, Madar, Cristian, Jones, Milissa U, Larson, Derek T, Ewers, Evan C, Bazan, Samantha, Fries, Anthony C, Maldonado, Carlos J, Simons, Mark P, Rozman, Julia S, Andronescu, Liana, Mende, Katrin, Tribble, David R, Agan, Brian K, Burgess, Timothy H, Pollett, Simon D, Powers, John H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214183/
https://www.ncbi.nlm.nih.gov/pubmed/35873301
http://dx.doi.org/10.1093/ofid/ofac275
_version_ 1784730953711616000
author Richard, Stephanie A
Epsi, Nusrat J
Lindholm, David A
Malloy, Allison M W
Maves, Ryan C
Berjohn, Catherine M
Lalani, Tahaniyat
Smith, Alfred G
Mody, Rupal M
Ganesan, Anuradha
Huprikar, Nikhil
Colombo, Rhonda E
Colombo, Christopher J
Madar, Cristian
Jones, Milissa U
Larson, Derek T
Ewers, Evan C
Bazan, Samantha
Fries, Anthony C
Maldonado, Carlos J
Simons, Mark P
Rozman, Julia S
Andronescu, Liana
Mende, Katrin
Tribble, David R
Agan, Brian K
Burgess, Timothy H
Pollett, Simon D
Powers, John H
author_facet Richard, Stephanie A
Epsi, Nusrat J
Lindholm, David A
Malloy, Allison M W
Maves, Ryan C
Berjohn, Catherine M
Lalani, Tahaniyat
Smith, Alfred G
Mody, Rupal M
Ganesan, Anuradha
Huprikar, Nikhil
Colombo, Rhonda E
Colombo, Christopher J
Madar, Cristian
Jones, Milissa U
Larson, Derek T
Ewers, Evan C
Bazan, Samantha
Fries, Anthony C
Maldonado, Carlos J
Simons, Mark P
Rozman, Julia S
Andronescu, Liana
Mende, Katrin
Tribble, David R
Agan, Brian K
Burgess, Timothy H
Pollett, Simon D
Powers, John H
author_sort Richard, Stephanie A
collection PubMed
description BACKGROUND: Patient-reported outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are an important measure of the full burden of coronavirus disease (COVID). Here, we examine how (1) infecting genotype and COVID-19 vaccination correlate with inFLUenza Patient-Reported Outcome (FLU-PRO) Plus score, including by symptom domains, and (2) FLU-PRO Plus scores predict return to usual activities and health. METHODS: The epidemiology, immunology, and clinical characteristics of pandemic infectious diseases (EPICC) study was implemented to describe the short- and long-term consequences of SARS-CoV-2 infection in a longitudinal, observational cohort. Multivariable linear regression models were run with FLU-PRO Plus scores as the outcome variable, and multivariable Cox proportional hazards models evaluated effects of FLU-PRO Plus scores on return to usual health or activities. RESULTS: Among the 764 participants included in this analysis, 63% were 18–44 years old, 40% were female, and 51% were White. Being fully vaccinated was associated with lower total scores (β = −0.39; 95% CI, −0.57 to −0.21). The Delta variant was associated with higher total scores (β = 0.25; 95% CI, 0.05 to 0.45). Participants with higher FLU-PRO Plus scores were less likely to report returning to usual health and activities (health: hazard ratio [HR], 0.46; 95% CI, 0.37 to 0.57; activities: HR, 0.56; 95% CI, 0.47 to 0.67). Fully vaccinated participants were more likely to report returning to usual activities (HR, 1.24; 95% CI, 1.04 to 1.48). CONCLUSIONS: Full SARS-CoV-2 vaccination is associated with decreased severity of patient-reported symptoms across multiple domains, which in turn is likely to be associated with earlier return to usual activities. In addition, infection with the Delta variant was associated with higher FLU-PRO Plus scores than previous variants, even after controlling for vaccination status.
format Online
Article
Text
id pubmed-9214183
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-92141832022-06-22 COVID-19 Patient-Reported Symptoms Using FLU-PRO Plus in a Cohort Study: Associations With Infecting Genotype, Vaccine History, and Return to Health Richard, Stephanie A Epsi, Nusrat J Lindholm, David A Malloy, Allison M W Maves, Ryan C Berjohn, Catherine M Lalani, Tahaniyat Smith, Alfred G Mody, Rupal M Ganesan, Anuradha Huprikar, Nikhil Colombo, Rhonda E Colombo, Christopher J Madar, Cristian Jones, Milissa U Larson, Derek T Ewers, Evan C Bazan, Samantha Fries, Anthony C Maldonado, Carlos J Simons, Mark P Rozman, Julia S Andronescu, Liana Mende, Katrin Tribble, David R Agan, Brian K Burgess, Timothy H Pollett, Simon D Powers, John H Open Forum Infect Dis Major Article BACKGROUND: Patient-reported outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are an important measure of the full burden of coronavirus disease (COVID). Here, we examine how (1) infecting genotype and COVID-19 vaccination correlate with inFLUenza Patient-Reported Outcome (FLU-PRO) Plus score, including by symptom domains, and (2) FLU-PRO Plus scores predict return to usual activities and health. METHODS: The epidemiology, immunology, and clinical characteristics of pandemic infectious diseases (EPICC) study was implemented to describe the short- and long-term consequences of SARS-CoV-2 infection in a longitudinal, observational cohort. Multivariable linear regression models were run with FLU-PRO Plus scores as the outcome variable, and multivariable Cox proportional hazards models evaluated effects of FLU-PRO Plus scores on return to usual health or activities. RESULTS: Among the 764 participants included in this analysis, 63% were 18–44 years old, 40% were female, and 51% were White. Being fully vaccinated was associated with lower total scores (β = −0.39; 95% CI, −0.57 to −0.21). The Delta variant was associated with higher total scores (β = 0.25; 95% CI, 0.05 to 0.45). Participants with higher FLU-PRO Plus scores were less likely to report returning to usual health and activities (health: hazard ratio [HR], 0.46; 95% CI, 0.37 to 0.57; activities: HR, 0.56; 95% CI, 0.47 to 0.67). Fully vaccinated participants were more likely to report returning to usual activities (HR, 1.24; 95% CI, 1.04 to 1.48). CONCLUSIONS: Full SARS-CoV-2 vaccination is associated with decreased severity of patient-reported symptoms across multiple domains, which in turn is likely to be associated with earlier return to usual activities. In addition, infection with the Delta variant was associated with higher FLU-PRO Plus scores than previous variants, even after controlling for vaccination status. Oxford University Press 2022-06-07 /pmc/articles/PMC9214183/ /pubmed/35873301 http://dx.doi.org/10.1093/ofid/ofac275 Text en Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2022 https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_modelThis work is written by (a) US Government employee(s) and is in the public domain in the US.
spellingShingle Major Article
Richard, Stephanie A
Epsi, Nusrat J
Lindholm, David A
Malloy, Allison M W
Maves, Ryan C
Berjohn, Catherine M
Lalani, Tahaniyat
Smith, Alfred G
Mody, Rupal M
Ganesan, Anuradha
Huprikar, Nikhil
Colombo, Rhonda E
Colombo, Christopher J
Madar, Cristian
Jones, Milissa U
Larson, Derek T
Ewers, Evan C
Bazan, Samantha
Fries, Anthony C
Maldonado, Carlos J
Simons, Mark P
Rozman, Julia S
Andronescu, Liana
Mende, Katrin
Tribble, David R
Agan, Brian K
Burgess, Timothy H
Pollett, Simon D
Powers, John H
COVID-19 Patient-Reported Symptoms Using FLU-PRO Plus in a Cohort Study: Associations With Infecting Genotype, Vaccine History, and Return to Health
title COVID-19 Patient-Reported Symptoms Using FLU-PRO Plus in a Cohort Study: Associations With Infecting Genotype, Vaccine History, and Return to Health
title_full COVID-19 Patient-Reported Symptoms Using FLU-PRO Plus in a Cohort Study: Associations With Infecting Genotype, Vaccine History, and Return to Health
title_fullStr COVID-19 Patient-Reported Symptoms Using FLU-PRO Plus in a Cohort Study: Associations With Infecting Genotype, Vaccine History, and Return to Health
title_full_unstemmed COVID-19 Patient-Reported Symptoms Using FLU-PRO Plus in a Cohort Study: Associations With Infecting Genotype, Vaccine History, and Return to Health
title_short COVID-19 Patient-Reported Symptoms Using FLU-PRO Plus in a Cohort Study: Associations With Infecting Genotype, Vaccine History, and Return to Health
title_sort covid-19 patient-reported symptoms using flu-pro plus in a cohort study: associations with infecting genotype, vaccine history, and return to health
topic Major Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214183/
https://www.ncbi.nlm.nih.gov/pubmed/35873301
http://dx.doi.org/10.1093/ofid/ofac275
work_keys_str_mv AT richardstephaniea covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT epsinusratj covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT lindholmdavida covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT malloyallisonmw covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT mavesryanc covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT berjohncatherinem covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT lalanitahaniyat covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT smithalfredg covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT modyrupalm covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT ganesananuradha covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT huprikarnikhil covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT colomborhondae covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT colombochristopherj covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT madarcristian covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT jonesmilissau covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT larsonderekt covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT ewersevanc covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT bazansamantha covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT friesanthonyc covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT maldonadocarlosj covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT simonsmarkp covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT rozmanjulias covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT andronesculiana covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT mendekatrin covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT tribbledavidr covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT aganbriank covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT burgesstimothyh covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT pollettsimond covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT powersjohnh covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth
AT covid19patientreportedsymptomsusingfluproplusinacohortstudyassociationswithinfectinggenotypevaccinehistoryandreturntohealth